
==== Front
Nucleic Acids ResNucleic Acids ResearchNucleic Acids Research0305-10481362-4962Oxford University Press 10.1093/nar/gkl39816935887Survey and SummaryRole of RNA helicases in HIV-1 replication Jeang Kuan-Teh *Yedavalli Venkat Molecular Virology Section, Laboratory of Molecular MedicineNIAID, NIH, Bethesda, MD 20892, USA*To whom correspondence should be addressed. Tel: +1 301 496 6680; Fax: +1 301 480 3686; Email: kj7e@nih.gov9 2006 9 2006 25 8 2006 34 15 4198 4205 28 3 2006 10 5 2006 11 5 2006 © 2006 The Author(s)2006This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Viruses are replication competent genomes which are relatively gene-poor. Even the largest viruses (i.e. Herpesviruses) encode only slightly >200 open reading frames (ORFs). However, because viruses replicate obligatorily inside cells, and considering that evolution may be driven by a principle of economy of scale, it is reasonable to surmise that many viruses have evolved the ability to co-opt cell-encoded proteins to provide needed surrogate functions. An in silico survey of viral sequence databases reveals that most positive-strand and double-stranded RNA viruses have ORFs for RNA helicases. On the other hand, the genomes of retroviruses are devoid of virally-encoded helicase. Here, we review in brief the notion that the human immunodeficiency virus (HIV-1) has adopted the ability to use one or more cellular RNA helicases for its replicative life cycle.
==== Body
INTRODUCTION
Helicases are enzymes that separate in an energy-dependent manner stretches of duplexed DNA and/or RNA into single-stranded components. Currently, based on characteristic motifs and the sequence comparisons, three superfamilies (SF1 through 3) and two smaller families (F4, F5) of helicases have been identified (1). Superfamily 1 and 2 contain helicases which share seven or more recognized signature amino acid motifs while SF3 and F4 and F5 helicases are characterized generally by three conserved motifs (2); the F4 and F5 proteins are largely bacterial and bacteriophage proteins. Currently, it should be cautioned that many ‘helicases’ are not bona fide helicases, but may only function as RNA translocases, perhaps to fulfill functions in the remodeling of ribonucleoprotein complexes (RNP).

DEAD-box and the related DEAH, DExH and DExD (3) helicases are the most numerous members of SF2 and are ubiquitously present in eukaryotic genomes. These helicases share eight conserved motifs and are commonly refered to as the DExH/D family of helicases. Humans, Arabidopsis and Saccharomyces have ∼38, 55 and 25 such entities, respectively (4). Differing from DNA helicases and DExH proteins, DEAD helicases are poor in unwinding long nucleic acid duplexes and are best suited for separating short RNA hybrids. DEAD-box proteins bind with high-affinity RNA–protein complexes while exhibiting little RNA sequence preference. This suggests that the specificity determinants for DEAD helicases may be through the recognition of protein factors. In this regard, a better understanding of the roles for DEAD proteins depends on the clear characterization of their respective interacting proteins.

Although the precise substrate for most helicases awaits definition, DEAD helicases are generally thought to participate pleiotropically in many aspects of RNA metabolism including transcription, mRNA splicing, mRNA export, translation, RNA stability and mitochondrial gene expression (5–8). Some examples of helicases and their attributed functions include the following. UAP56, Brr2, Prp16, Prp22 and Prp43 play roles in RNA-splicing (4,9), while Dbp5 (10,11) and DDX3 (12) chaperone RNAs from the nucleus into the cytoplasm. eIF4a and Ded1 serve for translation of mRNAs while Rh1B, Ski2, Dob1, Dhh1 helicases contribute to mRNA stability (4). Other DEAD helicases act in ribosome biogenesis through regulation of small nucleolar RNAs and ribosomal RNAs (rRNAs) interactions (13,14). Finally, Neurospora and Trypanosoma DEAD proteins contribute to mitochondrial gene expression (15,16); a Cryptococcus DEAD helicase is required for cryptococcosis pathogenesis (17), and the dipteran Chironomus tentans uses a hrp84 DEAD helicase to regulate mRNA transport from the nucleus into the cytoplasm onto polyribosomes (18).

Given that helicases significantly contribute to normal cellular metabolism, are they similarly essential to viruses? The operational answer appears to be a qualified ‘yes’. Indeed, when DEAD/DEAH-box helicase motif (InterPro IPR001410) was used to search the EMBL-EBI database, 1561 matches to individual viral sequence entries were found (), suggesting that many viruses have evolved to encode directly helicase or helicase-like proteins. The strongest biological evidence which supports the importance of a helicase in the virus life cycle comes from those viruses with an RNA genome. Hence, all positive-strand RNA viruses encode one or more helicase/helicase-like open reading frame (ORF) which, aside from the RNA-dependant RNA polymerase, is the most highly conserved viral sequence. Although less ubiquitous, helicases are also found in other types of viruses (see some examples listed in Table 1). Direct mutagenesis studies have confirmed that a helicase function is biologically required for the replication of many viruses including vaccinia virus (19), poliovirus (20), alphaviruses (21), brome mosaic virus (22), nidoviruses (23,24) and flaviviruses (25–27).

ROLE OF HELICASE IN THE HIV-1 LIFE CYCLE
In 1981, the first cases of acquired immunodeficiency syndrome (AIDS) were described in American homosexual men. Thereafter, within three short years, French and American scientists confirmed that the human immunodeficiency virus (HIV) is the causative agent for AIDS. In the ensuing 20 years, >20 million individuals have died from AIDS; and currently, in 2006, ∼50 million people worldwide are infected by HIV-1 with 3 million incremental AIDS deaths and 4–5 million new infections occurring annually. The magnitude of this burden casts urgency to medical research on HIV/AIDS.

HIV-1 is a retrovirus of the lentivirus genus with an RNA genome of ∼9 kilobases which encodes nine polypeptides. The major HIV-1 structural proteins are encoded by three genes, gag (group-specific antigen), pol (polymerase) and env (envelope), while the accessory proteins, Vif, Vpu, Vpr and Nef, and the regulatory proteins, Tat and Rev, are the primary translation products of multiply-spliced mRNA. HIV-1 infects CD4+ human T-cells and macrophages and integrates as a provirus into the host cell's DNA. Gene expression of HIV-1 is governed transcriptionally by a viral protein, Tat (28,29), via its binding to a nascent viral TAR RNA (30), and post-transcriptionally by a second viral protein Rev (31,32) through its association with the viral RRE RNA. Both Tat and Rev interact with several host cell proteins in their transcriptional and post-transcriptional functions (33). HIV-1 does not encode for any RNA helicase; however, findings suggest that host cell RNA helicases may be involved in the reverse transcription of HIV-1 RNA, in HIV-1 mRNA transcription and in the nucleus-to-cytoplasm transport of viral mRNA.

A recent unexpected finding revealed the possibility that an RNA helicase may potentially contribute roles in HIV-1 particle assembly and reverse transcription (34). Using proteomic analyses, Roy et al. (34) reported that the DEAH protein RNA helicase A (RHA) was found associated with HIV-1 Gag and packaged into HIV-1 virions in an RNA-dependent manner. When RHA was knocked down in cells, HIV-1 particles which were produced from these cells were significantly less infectious. This appears to be compatible with two possible explanations. First, it is conceivable that RHA participates in the formation of infectious virus particles either by shaping Gag–RNA interaction during viral particle assembly or by budding. Failure of RHA to properly restructure viral RNP could explain the observed reduced infectivity. Second, Roy et al. (34) reported evidence that HIV-1 particles that do not contain RHA showed reduced virion-endogenous reverse transcriptase activity. In this respect, it may be that RHA assists HIV-1 reverse transcriptase to more efficiently copy RNA by unwinding RNA secondary structure or by promoting the interaction of viral RNA with the nucleocapsid protein in order to assemble a better reverse transcription complex.

Separate from reverse transcription, the unwinding of highly structured RNAs might also be reasoned to be important for transcription (35). However, direct evidence for an RNA helicase role has been somewhat elusive. There are several examples which seemingly support an activity for RNA helicase in transcription. First, in vaccinia virus, it has been postulated that the NPH-II helicase assists transcription by strand-separating duplexed RNA structures to prevent R-loop formation behind the elongating RNA polymerase (36). Second, RHA has been invoked to provide a factor-recruitment role, bridging at the promoter the CREB-binding protein (37) and RNA polymerase II (37). Third, the p68 DEAD-box helicase was shown recently to be a novel transcriptional co-activator for p53's transcriptional function (38). Interestingly, in the latter two instances, neither the ATPase nor the helicase activity of RHA and p68 is apparently required for their attributed transcriptional roles.

For HIV-1, two recent studies provide clues that RNA helicases may also serve co-factor function for transcription from the viral long terminal repeat (LTR). Fujii et al. (39) observed that RHA conserves in its N-terminus two double-stranded RNA-binding (dsRBD) domains characterized previously for the TAR RNA-binding protein, TRBP (40,41). These investigators found in both reporter and virus replication assays that RHA activated, in a TAR RNA-binding dependant manner, HIV-1 LTR-directed transcription (39). Next, Cocude et al. (42) separately described that the expression of a DExH RNA helicase, RH116, was significantly induced after infection of HeLa-CD4 cells by HIV-1. RH116 was found localized in the nucleus of HIV-1 infected cells and was observed to augment the transcription of unspliced HIV-1 transcripts. While both studies offer tantalizing evidence for roles by two different RNA helicases in HIV-1 transcription, critical details on how the helicases function by binding to TAR RNA and how this binding might cooperate with the activities of the viral transcriptional activator, Tat, are lacking. Pending more direct experimental tests, it remains unclear whether RHA and RH116 provide direct roles in transcription or indirectly influence the milieu of polymerase II initiation/elongation at the LTR.

Downstream from transcription, the fate of HIV-1 encoded RNA is regulated at the step of export of unspliced/partially spliced moieties from the nucleus into the cytoplasm. Unspliced and partially spliced viral RNAs code for genomic RNAs that are packaged into progeny virions and structural proteins. Hence, the egress of these RNAs from the nucleus into the cytoplasm is critical to the life cycle of the virus. Exit of HIV RNAs from the nucleus is a significant issue because unspliced/partially spliced cellular mRNAs are routinely retained in and not permitted export from the nucleus (43–46). A large body of work has suggested an elegant solution to this conundrum. Thus, it was established that the HIV-1 encoded Rev protein binds a highly secondary structured element (Rev responsive element; RRE) present in all unspliced and partially spliced HIV transcripts (47–57); and this binding specifically distinguishes, for purposes of nuclear export, viral transcripts from cellular RNAs.

New evidence now suggests that RNA helicases are also co-factors for Rev-directed export of HIV-1 mRNAs (58). In its role of transporting unspliced and incompletely spliced viral RNAs from the nucleus, Rev directly interacts with nuclear export receptor CRM1 (59,60), and CRM1 is required for Rev-mediated export of HIV RNAs (59,61,62). A recent report provides data that an RNA helicase, DDX3, is an additional player in the Rev–CRM1–RRE complex (12). Thus, it was shown that DDX3 over-expression enhanced Rev-dependent, but not other export, pathway; and that DDX3 is a nucleo-cytoplasmic shuttling protein which binds CRM1 and Rev. Moreover, DDX3's necessity for Rev/RRE/CRM1 function was demonstrated by knock-down of cell endogenous DDX3. Finally, because DDX3 locates to nuclear pore complexes (NPC), Yedavalli et al. (12) further proposed that this human helicase, like the analogous yeast Dbp5p (11), may function with Rev/CRM1 to remodel and ‘thread’ large unspliced HIV-1 RNAs through the nuclear pore, facilitating their final release to the cytoplasmic side of the NPC.

The above DDX3 results are consistent with two additional papers which described similar findings for a related RNA helicase, DDX1. Thus, Pomerantz and co-workers (63) showed that DDX1 binds directly to the N-terminus of Rev and to the RRE-RNA motif and participates in the export of unspliced HIV-1 RNA from the nucleus to the cytoplasm. Additionally, they illustrated that reduced expression of DDX1 in astrocytes explains the previously observed tissue restricted function of HIV-1 Rev (64). Fully spliced viral mRNAs encoding for viral Tat, Rev and Nef, proteins have been shown previously to exit the nucleus using the cellular mRNA export pathway. Export of these mRNA may require the RNA helicase Dbp5 (65,66). As yet, the involvement of Dbp5 in export of spliced HIV-1 viral RNA has not been fully clarified.

The story of HIV-1 and RNA helicases is, however, likely to be more complex than and unlikely to conclude simply with RHA, RH116, DDX1 and DDX3 (Figure 1). HIV-1 RNAs are extensively regulated through splicing. Splicing is a multiple-step process requiring the recognition of splice sites by spliceosomes. It is generally believed that remodeling of RNA–RNA and RNA–protein interactions within the spliceosome is catalyzed by a family of DEAD/DExH box RNA helicases. To date, seven mammalian proteins that are RNA helicases have been implicated in mRNA splicing (67,68). Whether there is specific preference by subclasses of RNA helicases for viral mRNA splicing remains to be clarified. Moreover, how cellular RNA helicases might contribute to the translation of viral mRNAs also require further investigation.

Recently both Van't Wout et al. (69) and Krishnan and Zeichner (70) have provided evidence that the expression of several cellular RNA helicases including DDX24, DDX21, DDX18, DDX11 and DDX9 is modulated during HIV-1 infection; however, the precise cellular role and significance of these helicases for HIV-1 pathogenesis have not be characterized. Interestingly, Krishnan and Zeichner reported microarray data which examined the transition of HIV-1 infection from latency to productive replication, and found that several cellular RNA helicases were upregulated (71). For future understanding of functions, it will be important to design experiments which can segregate helicases which serve direct, although perhaps overlapping and redundant, roles on HIV-1 from those that might participate indirectly in the viral life cycle. Nevertheless, the convergence of evidence would support that several discrete cellular RNA helicases contribute importantly to the efficient execution of several steps in the HIV-1 replicative cycle.

HELICASE INHIBITORS AS FUTURE ANTIVIRALS?
Given that the HIV-1/AIDS disease burden has reached pandemic global proportions, new antiviral strategies that target molecularly delineated mechanisms used by this virus are urgently needed (72). Is there a possibility that host cell helicases can be therapeutic targets for anti-HIV-1 chemotherapy? Implicit within this question is the concept that one could attack a host cell protein in order to treat an infecting pathogen. Although targeting a cellular protein involved in a viral pathway risks obvious cytotoxicity, this approach avoids the inherent problem posed by rapid HIV-1 mutation to all currently utilized chemotherapeutics targeted to virus-encoded proteins. We note that inhibition of cell-encoded enzymes in medical therapy is not an unprecedented strategy. Suppression of angiotensin-converting enzyme (ACE) is widely used to treat hypertension, congestive heart failure, myocardial infarction, endothelial dysfunction and renal disease (73). Elsewhere, aromatase inhibitors have been used to treat hormone-dependent breast cancer (74), and inhibitors of cellular secretory proteases are contemplated for Alzheimer's disease (75). We recently inhibited the cellular polyprotein convertase, furin, at minimal toxicity to the cell in order to block HIV-1 replication (76). Thus, a priori exclusion of cellular helicase as an antiviral target is not warranted.

Guarded optimism that small molecule helicase inhibitors can be developed against viruses arises from encouraging progress in non-retroviral systems. Unlike HIV-1, human herpesviruses physically encode helicases. The herpes simplex virus UL5 and UL9 genes are helicases in superfamily 1 and 2, respectively (77). HSV UL5 together with UL8 and UL52 form a heterotrimeric helicase–primase complex responsible for unwinding duplex viral DNA at replication forks. Two recent studies provide proof-of-concept that the HSV helicase–primase can be targeted at low host cell toxicity by two new classes of drugs, amino-thiazolyphenyl-molecules (78) and thiazole amide derivatives (79). In addition, other studies suggest that the NS3 protein, a RNA helicase encoded by Hepatitis C virus and related West Nile virus and Japanese Encephalitis virus can be targeted to inhibit viral replication (80–82). This conceptual break through in drug development is important because it indicates that target discrimination between different helicases by small molecule inhibitors is possible. Of relevance to HIV-1, a synthetic immunomodulator Murabutide was shown recently to suppress HIV-1 replication in macrophages and T cells. Murabutide was shown to inhibit the activity of RNA helicase RH116, blocking its positive transcriptional activity for HIV-1 gene expression (42).

If one looks beyond the signature motifs conserved amongst helicases, then it becomes clear that the different proteins are widely divergent in their coding sequences. In principle, this suggests that individual helicases can be abrogated with specificity in a knowledge-directed manner. In theory, a helicase can be attacked by (i) inhibition of NTPase activity through direct competition for NTP binding, (ii) inhibition of substrate binding through direct competition at active site, (iii) allosteric mechanisms to affect NTP-binding/NTP hydrolysis and/or polynucleotide binding, and (iv) inhibition of unwinding activity by steric hinderance of helicase translocation along the polynucleotide substrate (83,84). Because the NTP-binding and substrate-binding pockets may be sufficiently similar between various helicases, specificity of inhibition through these sites will likely be extremely difficult, although perhaps not impossible. On the other hand, the tremendous variations in sequence and sizes of helicases, in their oligomerization states, in their discrete domains responsible for protein–protein interactions and/or for targeting to specific nucleic acids (85), and in their differential localizations within cells (86) offer interventional possibilities outside of the NTP- or polynucleotide-binding sites.

We are in the preliminary stages of screening ring-expanded nucleoside analogs found previously to be successful NTPase/helicase inhibitors of West Nile virus, Hepatitis C virus and Japanese encephalitis virus (81,82). We have observed that a few of these candidate inhibitors have substantial anti-HIV-1 activity at doses that do not incur cytotoxicity to cells treated in tissue culture for 1 week. Further studies are needed before concluding that these compounds exert specific inhibition of DDX3, one of the other cellular helicases, or some other target altogether.

CONCLUDING REMARKS AND PERSPECTIVES
There is another area where a cellular helicase activity and HIV-1 are likely to intersect. An emerging research focus is the role of small interfering RNAs (87) and microRNAs (miRNA) as innate cell defenses against viruses including HIV-1 (87–90). In human cells, the precursor for miRNA (pre-miRNA) is processed by DICER (Figure 2A) which is a ribonuclease with a bona fide RNA helicase domain (91,92). A surprising recent finding revealed that the human TRBP, which has been shown to be a potent binder of the HIV-1 TAR RNA RNA (40,41), is an indispensable dsRNA-binding partner of DICER which allows the latter to associate with pre-miRNA (91,92). Without TRBP, DICER's miRNA processing activity is lost. Thus an intriguing scenario can potentially unfold. Accordingly, whereas the ribonuclease–helicase protein DICER requires TRBP to process duplex-structured miRNAs in order that the cell can use such matured miRNAs for antiviral defense, it could be speculated that HIV-1 has evolved to restrict this defense by the ability to transcribe viral TAR RNA to squelch TRBP away from DICER (Y. Bennasser, M. L. Yeung and K. T. Jeang, manuscript submitted) (Figure 2B). If this thinking is correct, then HIV-1 has developed mechanisms not only to co-opt the active functions of a virus-propitious cellular helicase (i.e. DDX3) but also to inactivate the role of a second virus-pernicious helicase (i.e. DICER) for purposes of selfish gain.

In a separate perspective, virus infection can trigger through double-stranded viral RNAs an innate antiviral immune response. Thus viral dsRNAs can be recognized by cellular proteins [pattern-recognition receptors (PRRs)] which initiate antiviral responses by inducing the production of a variety of cytokines including type I interferons (IFN-α and IFN-β) and initiating additional inflammatory and adaptive immune responses. Recently, DExD/H RNA helicases such as RIG-1 (retinoic acid inducible gene-1) (93) and Mda5 (melanoma differentiation-associated gene 5) (94) have been identified as suppressors of viral replication by binding to virus associated dsRNA and activating type I interferon-dependent antiviral immunity. Over-expression of RIG-1 and Mda5 was found to enhance dsRNA induced type I interferon antiviral response. Currently, it remains speculative whether helicases like RIG-1 and Mda5 may recognize HIV-1 dsRNA and trigger an innate immune response. Intriguingly, several reports exist in the literature that HIV-1 infection does induce activation of type 1 interferons (95,96).

In conclusion, by studying helicase proteins one can gain insights into normal cellular metabolic processes, abnormal inherited human diseases (e.g. Bloom syndrome, Werner syndrome, Cockayne's syndrome and xeroderma pigmentosum; all diseases with mutations in cellular helicases), and remarkably also the biology of viruses.

We thank Anthony Elmo for assistance with preparation of manuscript. This work was supported in part by funds from the Intramural Research Program of the NIAID, NIH. Funding to pay the Open Access publication charges for this article was provided by NIAID, NIH.

Conflict of interest statement. None declared.

Figures and Tables
Figure 1 Schematic representation of the involvement of cellular RNA helicases in reverse transcription, transcription and post-transcriptional regulation of HIV-1 RNAs. RHA has been found to be a part of the HIV-1 virion and may participate in HIV-1 reverse transcription as well as particle assembly. RHA and RH116 have been reported to participate in HIV-1 transcription through interaction with the viral leader RNA, TAR. DDX1 and DDX3 act with Rev and RRE-containing RNAs for the transport of unspliced and partially spliced HIV-1 RNA from the nucleus to the cytoplasm.

Figure 2 Involvement of Dicer RNA helicase, TRBP and HIV-1 TAR RNA in the biology of the cell's micro RNA pathway. (A) Domain structure of Dicer proteins from mammals and Drosophila. (B) A schematic representation of a potential mechanism for TAR RNA-dependent suppression of Dicer activity. TAR RNA is suggested to bind to TRBP and decoy it from Dicer preventing Dicer-dependent miRNA processing activity.

Table 1 Examples of viral helicases

Sources	Superfamily 1	Superfamily 2	Superfamily 3	
Animal DNAvirus	UL5 (Herpesvirus)	UL9 (Herpesvirus) NPH-II (Poxvirus)	E1 (91) T antigen (SV40) NS1 (Parvovirus)	
Animal RNAvirus	NSP2 (Alphavirus)p70 (Rubella virus) Nsp13(SARS) ORF-1 (Hepatitis E)	NS3 (Flavivirus) NS3(Hepatitis C virus) NS3 (Pestivirus)	2C (19) 2C (Hepatitis A virus) 2C (Rhinovirus)
==== Refs
REFERENCES
1 Gorbalenya A.E. Koonin E.V.  Viral proteins containing the purine NTP-binding sequence pattern Nucleic Acids Res. 1989 17 8413 8440 2555771 
2 Caruthers J.M. McKay D.B.  Helicase structure and mechanism Curr. Opin. Struct. Biol. 2002 12 123 133 11839499 
3 Linder P. Lasko P.F. Ashburner M. Leroy P. Nielsen P.J. Nishi K. Schnier J. Slonimski P.P.  Birth of the D-E-A-D box Nature 1989 337 121 122 2563148 
4 Rocak S. Linder P.  DEAD-box proteins: the driving forces behind RNA metabolism Nature Rev. Mol. Cell Biol. 2004 5 232 241 14991003 
5 Lorsch J.R.  RNA chaperones exist and DEAD box proteins get a life Cell 2002 109 797 800 12110176 
6 Tanner N.K. Linder P.  DExD/H box RNA helicases: from generic motors to specific dissociation functions Mol. Cell 2001 8 251 262 11545728 
7 Luking A. Stahl U. Schmidt U.  The protein family of RNA helicases Crit. Rev. Biochem. Mol. Biol. 1998 33 259 296 9747670 
8 Linder P. Stutz F.  mRNA export: travelling with DEAD box proteins Curr. Biol. 2001 11 R961 R963 11728322 
9 de La C.J. Kressler D. Linder P.  Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families Trends Biochem. Sci. 1999 24 192 198 10322435 
10 Tseng S.S. Weaver P.L. Liu Y. Hitomi M. Tartakoff A.M. Chang T.H.  Dbp5p, a cytosolic RNA helicase, is required for poly(A)+ RNA export EMBO J. 1998 17 2651 2662 9564047 
11 Schmitt C. von Kobbe C. Bachi A. Pante N. Rodrigues J.P. Boscheron C. Rigaut G. Wilm M. Seraphin B. Carmo-Fonseca M.  Dbp5, a DEAD-box protein required for mRNA export, is recruited to the cytoplasmic fibrils of nuclear pore complex via a conserved interaction with CAN/Nup159p EMBO J. 1999 18 4332 4347 10428971 
12 Yedavalli V.S. Neuveut C. Chi Y.H. Kleiman L. Jeang K.T.  Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function Cell 2004 119 381 392 15507209 
13 Liang W.Q. Clark J.A. Fournier M.J.  The rRNA-processing function of the yeast U14 small nucleolar RNA can be rescued by a conserved RNA helicase-like protein Mol. Cell. Biol. 1997 17 4124 4132 9199348 
14 Daugeron M.C. Linder P.  Dbp7p, a putative ATP-dependent RNA helicase from Saccharomyces cerevisiae, is required for 60S ribosomal subunit assembly RNA 1998 4 566 581 9582098 
15 Seraphin B. Simon M. Boulet A. Faye G.  Mitochondrial splicing requires a protein from a novel helicase family Nature 1989 337 84 87 2535893 
16 Missel A. Souza A.E. Norskau G. Goringer H.U.  Disruption of a gene encoding a novel mitochondrial DEAD-box protein in Trypanosoma brucei affects edited mRNAs Mol. Cell. Biol. 1997 17 4895 4903 9271369 
17 Panepinto J. Liu L. Ramos J. Zhu X. Valyi-Nagy T. Eksi S. Fu J. Jaffe H.A. Wickes B. Williamson P.R.  The DEAD-box RNA helicase Vad1 regulates multiple virulence-associated genes in Cryptococcus neoformans J. Clin. Invest. 2005 115 632 641 15765146 
18 Nashchekin D. Zhao J. Visa N. Daneholt B.  A novel Ded1-like RNA helicase interacts with the Y-box protein ctYB-1 in nuclear mRNP particles and in polysomes J. Biol. Chem. 2006 281 14263 14272 16556597 
19 Gross C.H. Shuman S.  The nucleoside triphosphatase and helicase activities of vaccinia virus NPH-II are essential for virus replication J. Virol. 1998 72 4729 4736 9573237 
20 Pfister T. Wimmer E.  Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication J. Biol. Chem. 1999 274 6992 7001 10066753 
21 Gomez d.C. Ehsani N. Mikkola M.L. Garcia J.A. Kaariainen L.  RNA helicase activity of Semliki Forest virus replicase protein NSP2 FEBS Lett. 1999 448 19 22 10217401 
22 Ahola T. den Boon J.A. Ahlquist P.  Helicase and capping enzyme active site mutations in brome mosaic virus protein 1a cause defects in template recruitment, negative-strand RNA synthesis, and viral RNA capping J. Virol. 2000 74 8803 8811 10982322 
23 Seybert A. Hegyi A. Siddell S.G. Ziebuhr J.  The human coronavirus 229E superfamily 1 helicase has RNA and DNA duplex-unwinding activities with 5′-to-3′ polarity RNA 2000 6 1056 1068 10917600 
24 Seybert A. Posthuma C.C. van Dinten L.C. Snijder E.J. Gorbalenya A.E. Ziebuhr J.  A complex zinc finger controls the enzymatic activities of nidovirus helicases J. Virol. 2005 79 696 704 15613297 
25 Gu B. Liu C. Lin-Goerke J. Maley D.R. Gutshall L.L. Feltenberger C.A. Del Vecchio A.M.  The RNA helicase and nucleotide triphosphatase activities of the bovine viral diarrhea virus NS3 protein are essential for viral replication J. Virol. 2000 74 1794 1800 10644352 
26 Kolykhalov A.A. Mihalik K. Feinstone S.M. Rice C.M.  Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo J. Virol. 2000 74 2046 2051 10644379 
27 Matusan A.E. Pryor M.J. Davidson A.D. Wright P.J.  Mutagenesis of the Dengue virus type 2 NS3 protein within and outside helicase motifs: effects on enzyme activity and virus replication J. Virol. 2001 75 9633 9643 11559795 
28 Jeang K.T. Xiao H. Rich E.A.  Multifaceted activities of the HIV-1 transactivator of transcription, Tat J. Biol. Chem. 1999 274 28837 28840 10506122 
29 Wu Y.  HIV-1 gene expression: lessons from provirus and non-integrated DNA Retrovirology 2004 1 13 15219234 
30 Berkhout B. Silverman R.H. Jeang K.T.  Tat trans-activates the human immunodeficiency virus through a nascent RNA target Cell 1989 59 273 282 2478293 
31 Harris M.E. Hope T.J.  RNA export: insights from viral models Essays Biochem. 2000 36 115 127 12471907 
32 Cullen B.R.  Nuclear mRNA export: insights from virology Trends Biochem. Sci. 2003 28 419 424 12932730 
33 Cochrane A.W. McNally M.T. Mouland A.J.  The retrovirus RNA trafficking granule: from birth to maturity Retrovirology 2006 3 18 16545126 
34 Roy B.B. Hu J. Guo X. Russell R.S. Guo F. Kleiman L. Liang C.  Association of RNA helicase A with human immunodeficiency virus type 1 particles J. Biol. Chem. 2006 281 12625 12635 16527808 
35 Greive S.J. von Hippel P.H.  Thinking quantitatively about transcriptional regulation Nature Rev. Mol. Cell Biol. 2005 6 221 232 15714199 
36 Gross C.H. Shuman S.  Vaccinia virions lacking the RNA helicase nucleoside triphosphate phosphohydrolase II are defective in early transcription J. Virol. 1996 70 8549 8557 8970979 
37 Nakajima T. Uchida C. Anderson S.F. Lee C.G. Hurwitz J. Parvin J.D. Montminy M.  RNA helicase A mediates association of CBP with RNA polymerase II Cell 1997 90 1107 1112 9323138 
38 Bates G.J. Nicol S.M. Wilson B.J. Jacobs A.M. Bourdon J.C. Wardrop J. Gregory D.J. Lane D.P. Perkins N.D. Fuller-Pace F.V.  The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor EMBO J. 2005 24 543 553 15660129 
39 Fujii R. Okamoto M. Aratani S. Oishi T. Ohshima T. Taira K. Baba M. Fukamizu A. Nakajima T.  A role of RNA helicase A in cis-acting transactivation response element-mediated transcriptional regulation of human immunodeficiency virus type 1 J. Biol. Chem. 2001 276 5445 5451 11096080 
40 Gatignol A. Buckler-White A. Berkhout B. Jeang K.T.  Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR Science 1991 251 1597 1600 2011739 
41 Gatignol A. Buckler C. Jeang K.T.  Relatedness of an RNA-binding motif in human immunodeficiency virus type 1 TAR RNA-binding protein TRBP to human P1/dsI kinase and Drosophila staufen Mol. Cell. Biol. 1993 13 2193 2202 8455607 
42 Cocude C. Truong M.J. Billaut-Mulot O. Delsart V. Darcissac E. Capron A. Mouton Y. Bahr G.M.  A novel cellular RNA helicase, RH116, differentially regulates cell growth, programmed cell death and human immunodeficiency virus type 1 replication J. Gen. Virol. 2003 84 3215 3225 14645903 
43 Luo M.J. Reed R.  Splicing is required for rapid and efficient mRNA export in metazoans Proc. Natl Acad. Sci. USA 1999 96 14937 14942 10611316 
44 Stutz F. Bachi A. Doerks T. Braun I.C. Seraphin B. Wilm M. Bork P. Izaurralde E.  REF, an evolutionary conserved family of hnRNP-like proteins, interacts with TAP/Mex67p and participates in mRNA nuclear export RNA 2000 6 638 650 10786854 
45 Strasser K. Bassler J. Hurt E.  Binding of the Mex67p/Mtr2p heterodimer to FXFG, GLFG, and FG repeat nucleoporins is essential for nuclear mRNA export J. Cell Biol. 2000 150 695 706 10952996 
46 Zhou Z. Luo M.J. Straesser K. Katahira J. Hurt E. Reed R.  The protein Aly links pre-messenger-RNA splicing to nuclear export in metazoans Nature 2000 407 401 405 11014198 
47 Feinberg M.B. Jarrett R.F. Aldovini A. Gallo R.C. Wong-Staal F.  HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA Cell 1986 46 807 817 3638988 
48 Zapp M.L. Green M.R.  Sequence-specific RNA binding by the HIV-1 Rev protein Nature 1989 342 714 716 2556643 
49 Dayton E.T. Powell D.M. Dayton A.I.  Functional analysis of CAR, the target sequence for the Rev protein of HIV-1 Science 1989 246 1625 1629 2688093 
50 Felber B.K. Hadzopoulou-Cladaras M. Cladaras C. Copeland T. Pavlakis G.N.  rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA Proc. Natl Acad. Sci. USA 1989 86 1495 1499 2784208 
51 Chang D.D. Sharp P.A.  Regulation by HIV Rev depends upon recognition of splice sites Cell 1989 59 789 795 2686839 
52 Hope T.J. McDonald D. Huang X.J. Low J. Parslow T.G.  Mutational analysis of the human immunodeficiency virus type 1 Rev transactivator: essential residues near the amino terminus J. Virol. 1990 64 5360 5366 2120472 
53 Holland S.M. Ahmad N. Maitra R.K. Wingfield P. Venkatesan S.  Human immunodeficiency virus rev protein recognizes a target sequence in rev-responsive element RNA within the context of RNA secondary structure J. Virol. 1990 64 5966 5975 2243382 
54 Rosen C.A. Terwilliger E. Dayton A. Sodroski J.G. Haseltine W.A.  Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus Proc. Natl Acad. Sci. USA 1988 85 2071 2075 2832844 
55 Kjems J. Brown M. Chang D.D. Sharp P.A.  Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element Proc. Natl Acad. Sci. USA 1991 88 683 687 1992459 
56 Knight D.M. Flomerfelt F.A. Ghrayeb J.  Expression of the art/trs protein of HIV and study of its role in viral envelope synthesis Science 1987 236 837 840 3033827 
57 Malim M.H. Hauber J. Le S.Y. Maizel J.V. Cullen B.R.  The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA Nature 1989 338 254 257 2784194 
58 Dayton A.I.  Within you, without you: HIV-1 Rev and RNA export Retrovirology 2004 1 35 15516266 
59 Fornerod M. Ohno M. Yoshida M. Mattaj I.W.  CRM1 is an export receptor for leucine-rich nuclear export signals Cell 1997 90 1051 1060 9323133 
60 Neville M. Stutz F. Lee L. Davis L.I. Rosbash M.  The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export Curr. Biol. 1997 7 767 775 9368759 
61 Bogerd H.P. Echarri A. Ross T.M. Cullen B.R.  Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1 J. Virol. 1998 72 8627 8635 9765402 
62 Fukuda M. Asano S. Nakamura T. Adachi M. Yoshida M. Yanagida M. Nishida E.  CRM1 is responsible for intracellular transport mediated by the nuclear export signal Nature 1997 390 308 311 9384386 
63 Fang J. Kubota S. Yang B. Zhou N. Zhang H. Godbout R. Pomerantz R.J.  A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev Virology 2004 330 471 480 15567440 
64 Fang J. Acheampong E. Dave R. Wang F. Mukhtar M. Pomerantz R.J.  The RNA helicase DDX1 is involved in restricted HIV-1 Rev function in human astrocytes Virology 2005 336 299 307 15892970 
65 Snay-Hodge C.A. Colot H.V. Goldstein A.L. Cole C.N.  Dbp5p/Rat8p is a yeast nuclear pore-associated DEAD-box protein essential for RNA export EMBO J. 1998 17 2663 2676 9564048 
66 Tseng S.S. Weaver P.L. Liu Y. Hitomi M. Tartakoff A.M. Chang T.H.  Dbp5p, a cytosolic RNA helicase, is required for poly(A)+ RNA export EMBO J. 1998 17 2651 2662 9564047 
67 Hamm J. Lamond A.I.  Spliceosome assembly: the unwinding role of DEAD-box proteins Curr. Biol. 1998 8 R532 R534 9705927 
68 Rappsilber J. Ryder U. Lamond A.I. Mann M.  Large-scale proteomic analysis of the human spliceosome Genome Res. 2002 12 1231 1245 12176931 
69 Van't Wout A.B. Lehrman G.K. Mikheeva S.A. O'Keeffe G.C. Katze M.G. Bumgarner R.E. Geiss G.K. Mullins J.I.  Cellular gene expression upon human immunodeficiency virus type 1 infection of CD4(+)-T-cell lines J. Virol. 2003 77 1392 1402 12502855 
70 Krishnan V. Zeichner S.L.  Alterations in the expression of DEAD-box and other RNA binding proteins during HIV-1 replication Retrovirology 2004 1 42 15588285 
71 Krishnan V. Zeichner S.L.  Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency J. Virol. 2004 78 9458 9473 15308739 
72 Nielsen M.H. Pedersen F.S. Kjems J.  Molecular strategies to inhibit HIV-1 replication Retrovirology 2005 2 10 15715913 
73 Menard J. Patchett A.A.  Angiotensin-converting enzyme inhibitors Adv. Protein Chem. 2001 56 13 75 11329852 
74 Miller W.R. Anderson T.J. Evans D.B. Krause A. Hampton G. Dixon J.M.  An integrated view of aromatase and its inhibition J. Steroid Biochem. Mol. Biol. 2003 86 413 421 14623539 
75 Hook V.Y. Reisine T.D.  Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway J. Neurosci. Res. 2003 74 393 405 14598316 
76 Kibler K.V. Miyazato A. Yedavalli V.S. Dayton A.I. Jacobs B.L. Dapolito G. Kim S.J. Jeang K.T.  Polyarginine inhibits gp160 processing by furin and suppresses productive human immunodeficiency virus type 1 infection J. Biol. Chem. 2004 279 49055 49063 15371436 
77 Marintcheva B. Weller S.K.  A tale of two HSV-1 helicases: roles of phage and animal virus helicases in DNA replication and recombination Prog. Nucleic Acid Res. Mol. Biol. 2001 70 77 118 11642367 
78 Crute J.J. Grygon C.A. Hargrave K.D. Simoneau B. Faucher A.M. Bolger G. Kibler P. Liuzzi M. Cordingley M.G.  Herpes simplex virus helicase–primase inhibitors are active in animal models of human disease Nature Med. 2002 8 386 391 11927945 
79 Kleymann G. Fischer R. Betz U.A. Hendrix M. Bender W. Schneider U. Handke G. Eckenberg P. Hewlett G. Pevzner V.  New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease Nature Med. 2002 8 392 398 11927946 
80 Borowski P. Deinert J. Schalinski S. Bretner M. Ginalski K. Kulikowski T. Shugar D.  Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses Eur. J. Biochem. 2003 270 1645 1653 12694177 
81 Zhang N. Chen H.M. Koch V. Schmitz H. Liao C.L. Bretner M. Bhadti V.S. Fattom A.I. Naso R.B. Hosmane R.S.  Ring-expanded (‘fat’) nucleoside and nucleotide analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus J. Med. Chem. 2003 46 4149 4164 12954067 
82 Zhang N. Chen H.M. Koch V. Schmitz H. Minczuk M. Stepien P. Fattom A.I. Naso R.B. Kalicharran K. Borowski P.  Potent inhibition of NTPase/helicase of the West Nile Virus by ring-expanded (‘fat’) nucleoside analogues J. Med. Chem. 2003 46 4776 4789 14561097 
83 Borowski P. Schalinski S. Schmitz H.  Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy Antiviral Res. 2002 55 397 412 12206878 
84 Kwong A.D. Rao B.G. Jeang K.T.  Viral and cellular RNA helicases as antiviral targets Nature Rev. Drug Discov. 2005 4 845 853 16184083 
85 Singleton M.R. Wigley D.B.  Modularity and specialization in superfamily 1 and 2 helicases J. Bacteriol. 2002 184 1819 1826 11889086 
86 Kadare G. Haenni A.L.  Virus-encoded RNA helicases J. Virol. 1997 71 2583 2590 9060609 
87 Bennasser Y. Le S.Y. Benkirane M. Jeang K.T.  Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing Immunity. 2005 22 607 619 15894278 
88 Omoto S. Ito M. Tsutsumi Y. Ichikawa Y. Okuyama H. Brisibe E.A. Saksena N.K. Fujii Y.R.  HIV-1 nef suppression by virally encoded microRNA Retrovirology 2004 1 44 15601474 
89 Bennasser Y. Le S.Y. Yeung M.L. Jeang K.T.  HIV-1 encoded candidate micro-RNAs and their cellular targets Retrovirology 2004 1 43 15601472 
90 Mak J.  RNA interference: more than a research tool in the vertebrates' adaptive immunity Retrovirology 2005 2 35 15916707 
91 Forstemann K. Tomari Y. Du T. Vagin V.V. Denli A.M. Bratu D.P. Klattenhoff C. Theurkauf W.E. Zamore P.D.  Normal microRNA maturation and germ-line stem cell maintenance requires Loquacious, a double-stranded RNA-binding domain protein PLoS Biol. 2005 3 e236 15918770 
92 Chendrimada T.P. Gregory R.I. Kumaraswamy E. Norman J. Cooch N. Nishikura K. Shiekhattar R.  TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing Nature 2005 436 740 744 15973356 
93 Yoneyama M. Kikuchi M. Natsukawa T. Shinobu N. Imaizumi T. Miyagishi M. Taira K. Akira S. Fujita T.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses Nature Immunol. 2004 5 730 737 15208624 
94 Kang D.C. Gopalkrishnan R.V. Wu Q. Jankowsky E. Pyle A.M. Fisher P.B.  mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties Proc. Natl Acad. Sci. USA 2002 99 637 642 11805321 
95 Read S.E. Williams B.R. Coates R.A. Evans W.K. Fanning M.M. Garvey M.B. Shepherd F.A.  Elevated levels of interferon-induced 2′-5′ oligoadenylate synthetase in generalized persistent lymphadenopathy and the acquired immunodeficiency syndrome J. Infect. Dis. 1985 152 466 472 2411826 
96 Maitra R.K. McMillan N.A. Desai S. McSwiggen J. Hovanessian A.G. Sen G. Williams B.R. Silverman R.H.  HIV-1 TAR RNA has an intrinsic ability to activate interferon-inducible enzymes Virology 1994 204 823 827 7524241

